ENCLAI Daily · Article of the day 03 Oct 2026 · ENCLAI Editorial

Tirabrutinib shows 67% response rate in relapsed or refractory primary CNS lymphoma

NEW MEDICAL STUDY EXPLAINED · 03 OCTOBER 2026Tirabrutinib shows 67% response rate inrelapsed or refractory primary CNSlymphomaPubMed 42821736Early-phase /non-randomised trial ·Study typeBloodjournal1 Oct 2026publishedIn a phase 2 trial, once-daily oral tirabrutinib monotherapyachieved an overall response rate of 67% (95% confidenceinterval, 52-80) in adults with relapsed or refractory primarycentral nervous system lymphoma.What the study found1Among 48 enrolled patients with a median follow-up of 11.5 months, theoverall response rate was 67% (95% confidence interval, 52-80).2The complete response rate was 44% (95% confidence interval, 29-59),with a median duration of response of 9.3 months (95% confidenceinterval, 4.6-14.6).3The median time to response was 1.0 month, with a range of 0.9 to 3.7.Who it applies toThe study enrolled adults withrelapsed or refractory primary centralnervous system lymphoma in the UnitedStates. Participants were required tohave disease that progressed on orafter at least one high-dosemethotrexate-based therapy.What it does not establishTreatment-related treatment-emergentadverse events occurred in 36 patients(75%), most commonly anemia (19%),maculopapular rash (17%), fatigue(15%), neutropenia (15%),lymphocytopenia (15%), pruritus (15%),and other rash (15%).The authors' conclusion“In a phase 2 trial, once-daily oral tirabrutinib monotherapy achievedan overall response rate of 67% (95% confidence interval, 52-80) inadults with relapsed or refractory primary central nervous systemlymphoma.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 42821736 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. In a phase 2 trial, once-daily oral tirabrutinib monotherapy achieved an overall response rate of 67% (95% confidence interval, 52-80) in adults with relapsed or refractory primary central nervous system lymphoma.
  2. Among 48 enrolled patients with a median follow-up of 11.5 months, the overall response rate was 67% (95% confidence interval, 52-80).
  3. The complete response rate was 44% (95% confidence interval, 29-59), with a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).
  4. The median time to response was 1.0 month, with a range of 0.9 to 3.7.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a phase 2 trial, once-daily oral tirabrutinib monotherapy achieved an overall response rate of 67% (95% confidence interval, 52-80) in adults with relapsed or refractory primary central nervous system lymphoma. The study also reported a complete response rate of 44% (95% confidence interval, 29-59) and a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).

Who the findings apply to

The study enrolled adults with relapsed or refractory primary central nervous system lymphoma in the United States.

Participants were required to have disease that progressed on or after at least one high-dose methotrexate-based therapy.

Why this matters

Primary central nervous system lymphoma is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis and no established standard of care for relapsed or refractory disease. The trial results indicate that tirabrutinib, a second-generation Bruton tyrosine kinase inhibitor, produced rapid and durable responses in this population, addressing a significant unmet medical need.

What the study found

Among 48 enrolled patients with a median follow-up of 11.5 months, the overall response rate was 67% (95% confidence interval, 52-80).

The complete response rate was 44% (95% confidence interval, 29-59), with a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).

The median time to response was 1.0 month, with a range of 0.9 to 3.7.

Responses were assessed by an independent review committee in this open-label phase 2 study.

What the result does not establish

Treatment-related treatment-emergent adverse events occurred in 36 patients (75%), most commonly anemia (19%), maculopapular rash (17%), fatigue (15%), neutropenia (15%), lymphocytopenia (15%), pruritus (15%), and other rash (15%).

Grade 3 or higher treatment-related adverse events occurred in 13 patients (27%), most commonly neutropenia (8%) and maculopapular rash (6%).

One death from bronchopulmonary aspergillosis was considered treatment-related.

The study was a single-arm phase 2 trial, so efficacy results are not compared against a control group.

Authors’ conclusion

“In patients with R/R PCNSL, once-daily oral tirabrutinib monotherapy resulted in rapid and durable responses and demonstrated a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04947319.”

Trial registration

NCT04947319

Registered titleStudy of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Registry statusPhase 2, interventional, active not recruiting
Lead sponsorOno Pharmaceutical Co. Ltd
Registered size119 participants — actual enrolment
Where39 sites in 1 country (United States)
Registered primary outcomes
  • Overall response rate (ORR) (Part A) (time frame: 1 year)
  • Tirabrutinib dose estimate (Part B) (time frame: 1 month)
  • Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction (Part B) (time frame: 4 months)
  • and 1 more

Primary endpoint named in the abstract: overall response rate (ORR), and secondary endpoints included complete response (CR) rate, duration of response…. Compare the two: a change of primary endpoint after registration matters.

  • Start: Dec 2021
  • Paper published: Oct 2026
  • Completion: Mar 2027 (estimated)
  • Primary completion: Mar 2027 (estimated)
Filled circle: date reached. Open circle: date the registry lists as estimated.

ClinicalTrials.gov record as held by ENCLAI, last updated Oct 2025. The registry status may have changed since; the link shows the current record.

Study and sources

Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial

Early-phase / non-randomised trial · Phase 2 · Blood · 2026-10-01

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.